TY - JOUR
T1 - Tumor targeting via EPR
T2 - Strategies to enhance patient responses
AU - Golombek, Susanne K.
AU - May, Jan Niklas
AU - Theek, Benjamin
AU - Appold, Lia
AU - Drude, Natascha
AU - Kiessling, Fabian
AU - Lammers, Twan
PY - 2018/5
Y1 - 2018/5
N2 - The tumor accumulation of nanomedicines relies on the enhanced permeability and retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there is a large inter- and intra-individual heterogeneity in EPR-mediated tumor targeting, explaining the heterogeneous outcomes of clinical trials in which nanomedicine formulations have been evaluated. To address this heterogeneity, as in other areas of oncology drug development, we have to move away from a one-size-fits-all tumor targeting approach, towards methods that can be employed to individualize and improve nanomedicine treatments. To this end, efforts have to be invested in better understanding the nature, the complexity and the heterogeneity of the EPR effect, and in establishing systems and strategies to enhance, combine, bypass and image EPR-based tumor targeting. In the present manuscript, we summarize key studies in which these strategies are explored, and we discuss how these approaches can be employed to enhance patient responses.
AB - The tumor accumulation of nanomedicines relies on the enhanced permeability and retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there is a large inter- and intra-individual heterogeneity in EPR-mediated tumor targeting, explaining the heterogeneous outcomes of clinical trials in which nanomedicine formulations have been evaluated. To address this heterogeneity, as in other areas of oncology drug development, we have to move away from a one-size-fits-all tumor targeting approach, towards methods that can be employed to individualize and improve nanomedicine treatments. To this end, efforts have to be invested in better understanding the nature, the complexity and the heterogeneity of the EPR effect, and in establishing systems and strategies to enhance, combine, bypass and image EPR-based tumor targeting. In the present manuscript, we summarize key studies in which these strategies are explored, and we discuss how these approaches can be employed to enhance patient responses.
KW - Cancer
KW - Drug delivery
KW - EPR
KW - Nanomedicine
KW - Tumor targeting
UR - http://www.scopus.com/inward/record.url?scp=85051952921&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2018.07.007
DO - 10.1016/j.addr.2018.07.007
M3 - Review article
C2 - 30009886
AN - SCOPUS:85051952921
VL - 130
SP - 17
EP - 38
JO - Advanced drug delivery reviews
JF - Advanced drug delivery reviews
SN - 0169-409X
ER -